Source: FinanzNachrichten

Cycle Pharmaceuticals: Cycle Pharmaceuticals Limited: New US product launch, VENXXIVA (tiopronin) Delayed-Release Tablets for the treatment of cystinuria

Cycle Pharmaceuticals Limited (Cycle) announced today the launch of VENXXIVA (tiopronin) Delayed-Release Tablets, for the treatment of cystinuria, approved by the US Food and Drug Administration (...

Read full article »
Cycle Pharmaceuticals's Competitors | Cycle Pharmaceuticals's News | Cycle Pharmaceuticals's Financials
Stay up-to-date with the latest news on Cycle Pharmaceuticals
Est. Annual Revenue
$25-100M
Est. Employees
25-100
James Harrison's photo - Chairman & CEO of Cycle Pharmaceuticals

Chairman & CEO

James Harrison

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Cycle Pharmaceuticals